erlotinib Articles
OSI's Tarceva to debut in Japan Dec 18
24 December 2007
Tarceva helps OSI reach $30M 3rd-qtr profit
12 November 2007
UPDATE: Thailand negotiations on drug prices continue
29 October 2007
Tarceva cleared for new indication in Japan
29 October 2007
Thailand negotiations on drug prices continue
29 October 2007
Roche cuts Tarceva price to help NICE case
8 October 2007
OSI and Aveo sign $10M development deal
8 October 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
Pfizer initiates Ph III Sutent trial in NSCLC
17 September 2007
Tykerb side effects are "manageable," study
13 August 2007
Tarceva helps boost OSI's 2nd-qtr sales 42%
13 August 2007
Cancer, RA drugs boost Genentech
16 July 2007
Japan anticancer market to grow 43% by 2015
11 June 2007
Roche's Tarceva boosts survival 22%
7 May 2007
UK's NICE says "no" to Roche's Tarceva
19 March 2007
AstraZeneca begins Ph III Zactima trial
5 March 2007
Japan stock market week to Feb 26, 2007
5 March 2007
EC clears Roche's Tarceva in pancreatic cancer
5 February 2007
Roche says Tarceva is cost-effective in study
5 February 2007
Tarceva gets CHMP OK for pancreatic cancer
22 December 2006
UK should "reform NHS, scrap NICE and allow DTC advertising"
20 November 2006
EntreMed's ENMD-1420 active in preclinical trial
20 November 2006
Introgen gains rights to therapies combining EGFr inhibitors
13 November 2006
Hana Biosci in-licenses menadione
23 October 2006
Roche reports sales of $23.89B for first three qtrs of 2006, a 4.7% share of global market
23 October 2006
Genentech's 3rd-qtr GAAP net leaps 58%
16 October 2006
Chugai to set up oncology unit
9 October 2006
Roche asks CHMP to re-examine Tarceva data
11 September 2006
GPC initiates new Ph II satraplatin trial
14 August 2006
GPC Biotech begins Ph II satraplatin study in NSCLC
7 August 2006
Tarceva gets negative opinion from CHMP
7 August 2006
Roche's 1st-qtr 2006 sales rise 22%
8 May 2006
Chugai/Roche file Avastin in Japan
1 May 2006
Chugai submits Japan NDA for OSI's Tarceva
24 April 2006
Good animal data for TopoTarget/Curagen's PXD101
10 April 2006
OSI Pharma sees 2005 losses fall to $157.1M
20 March 2006
OSI's Tarceva earns $25.0M in 4th-qtr 2005
13 February 2006
Licensing pivotal to pharma industry evolving strategies
19 December 2005
Tentative FDA OK for OSI/Genentech's Tarceva
19 September 2005
OSI's Tarceva: FDA reviews new indication
15 August 2005
Roche Rx sales grow three times world rate
25 July 2005
Tarceva approved in Canada for lung cancer
25 July 2005
OSI's Tarceva "not limited to EGFR patient sub-set"
18 July 2005
OSI files sNDA on Tarceva with US FDA
18 July 2005
Stock Commentary - Europe
4 July 2005
CHMP recommends Roche's Tarceva
4 July 2005
OSI Pharma gets US patent for crystalline Tarceva
13 June 2005
Tarceva sNDA filed with US FDA
9 May 2005
Genasense shows strong combination performance
25 April 2005
Roche 1st-qtr sales, up 17%, beat estimates
25 April 2005
OSI's Tarceva approved in Switzerland
28 March 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
ViroLogic's eTAG to predict cancer treatment outcome?
7 February 2005
New product launches in 2004
31 January 2005
Editor's views on biotech; clinical trial transparency
17 January 2005
New cancer drug costs too high for some?
25 October 2004
Stock Commentary - Europe
27 September 2004
New Phase III results indicate versatility of Tarceva in treating range of cancers
27 September 2004
Stock Commentary - Europe
6 September 2004
Tarceva filed in EU for advanced NSCL cancer
30 August 2004
Tarceva NDA filing completed in USA
9 August 2004
Stock Commentary - New York
21 June 2004
Stock Commentary - Europe
21 June 2004
OSI and Genentech sign agreements for Tarceva
21 June 2004
Stock Commentary - New York
14 June 2004
Tarceva shows promise for NSCLC
14 June 2004
Stock Commentary - New York
3 May 2004
Stock Commentary - Europe
3 May 2004
OSI/Genentech/Roche's Tarceva filed in USA
2 February 2004
Ph III Tarceva studies disappoint
6 October 2003
Tarceva Ph II brain cancer study starts
18 August 2003
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
